Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449646 | 0.84 | CYP19A1 (0.44) | CYP19A1NPC1IDH1ALDH1A1MAPT | |
| SCHEMBL6450284 | 0.84 | EPHX2 (0.36) | HSD11B1NPC1TRPV1RBP4 | |
| SCHEMBL6460828 | 0.83 | CYP19A1 (0.43) | HSD11B1CYP19A1NPC1IDH1NFE2L2 | |
| SCHEMBL6451085 | 0.78 | IDH1 (0.43) | HSD11B1NPC1IDH1NFE2L2ALDH1A1 | |
| SCHEMBL6448755 | 0.78 | MAPT (0.53) | CYP19A1NPC1IDH1ALDH1A1MAPT | |
| SCHEMBL6454678 | 0.73 | CYP19A1 (0.42) | HSD11B1CYP19A1NPC1IDH1ALDH1A1 | |
| SCHEMBL6450174 | 0.71 | HSD11B1 (0.42) | HSD11B1NPC1NFE2L2ALDH1A1GALR2 | |
| SCHEMBL6449959 | 0.70 | CYP19A1 (0.43) | CYP19A1NPC1IDH1NFE2L2ALDH1A1 | |
| SCHEMBL29454959 | 0.70 | EPHX2 (0.47) | HSD11B1TRPV1MAPTTSHRRBP4 | |
| SCHEMBL6450017 | 0.69 | GRK6 (0.44) | CYP19A1NPC1IDH1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | HSD11B1 357/4885CYP19A1 523/4885NPC1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.